Cat. No. 1293
Chemical Name: 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione
Biological ActivityDNA topoisomerase I inhibitor. Exhibits a different inhibitory mechanism to camptothecin (Cat. No. 1100). Induces apoptosis in a variety of cell lines, including prostate cancer and promyelocytic leukemia cells; blocks the cell cycle in G0/G1. Also has effects on DNA topoisomerase II, NF-κB, AP-1, and JNK.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Li et al (1993) Beta-Lapachone, a novel topoisomerase I inhibitor with a mode of action different from camptothecin. J.Biol.Chem. 268 22463. PMID: 8226754.
Wuerzberger et al (1998) Induction of apoptosis in MCF-7:WS8 breast cancer cells by β-Lapachone. Cancer Res. 58 1876. PMID: 9581828.
Manna et al (1999) Suppression of tumor necrosis factor-activated nuclear transcription factor-κB, activator protein-1, c-Jun N-terminal kinase, and apoptosis by β lapachone. Biochem.Pharmacol. 57 763. PMID: 10075082.
Shiah et al (1999) Activation of c-Jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor β-lapachone-induced apoptosis through an oxidation-dependent pathway Cancer Res. 59 391. PMID: 9927052.
If you know of a relevant citation for this product please let us know.
Keywords: b-Lapachone, supplier, DNA, topoisomerase, I, inhibitors, apoptosis, proapoptotic, b-lapachone, beta-lapachone, β-lapachone
Find multiple products by catalog number
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.